AbbVie Inc vs Weibo Corp — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while Weibo Corp trades at $7.87 (market cap $1.93B). The key difference: AbbVie Inc is far larger — about 227× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.65%). Which is the better fit depends on your goals.
| ABBV | WB | |
|---|---|---|
Market Cap | $438.19B | $1.93B |
Sector | Health | Media |
52-Week High | $263.58 | $12.83 |
52-Week Low | $197.38 | $7.20 |
Enterprise Value | $502.45B | $1.20B |
Dividend Yield | 2.79% | 7.65% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Weibo (WB) trades at $7.94, up 0.76% today, with neutral technical signals and strong fundamental metrics including a low P/E of 5.55 and robust 21.15% net income margin. Recent earnings show three consecutive quarterly misses but Q2 2026 results are pending. The company maintains solid cash flow generation with $519M operating cash flow in 2025, while analyst sentiment is mixed with 45% buy ratings.
WB presents value opportunity with discounted valuation metrics and strong profitability, though competitive pressures from Douyin and WeChat create headwinds. The stock's 8% dividend yield and cash-rich balance sheet provide downside protection, but investor sentiment remains cautious pending Q2 earnings results on August 19, 2026.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →